Comparison of HPV positivity, sensitivity and viral load between four vaginal self collection devices and urine

Jack Cuzick

Louise Cadman, Caroline Reuter, Michelle Kleeman, Mark Jitlal, Janet Austin, Lesley Ashdown-Barr, Anna Parberry, Tony Hollingworth, Attila Lorincz


Wolfson Institute of Preventive Medicine

Queen Mary University of London London, United Kingdom






Louise Cadman 1965 - 2020



Disclosures

- Becton Dickinson Travel expenses, Research support to Institution
- Qiagen Research support to Institution
- Aprovix AB (donated Qvintips)
- eve MEDICAL (donated HerSwabs)
- Novosanis (donated Colli-Pee™devices)

Flowchart



Devices



Digene swab
(WD, Transported wet)

HerSwab (HS)



Qvintip (QT)



Colli-Pee (Urine)

FLOQswab (FS)

hrHPV positivity rates by sample order

	hrHPV Pos		
Device	First sample	Second Sample	P-value
Digene STM	69	72	0.61
FLOQswab dry	69	71	0.90
Qvintip dry	67	63	0.52
Herswab dry	58	64	0.43

No impact of sample order

hrHPV positivity rates and sensitivity by device Combined samples – no adjustment for cellularity


HPV positive: Ct ≤ 34.2

		All samples	5	CIN2+		
Device	N	Positive (%) (95% CI)	P-value vs WD	N	Positive (%) (95% CI)	P-value vs WD
Wet Digene Dacron (WD)	300	70.3 (64.8, 75.4)	-	69	85.5 (75.0, 92.8)	-
FLOQswab dry (FS)	300	70.0 (64.5, 75.1)	0.99	69	84.1 (73.3, 91.8)	0.99
Qvintip dry (QT)	296	65.2 (59.5, 70.6)	0.19	62	77.4 (65.0, 87.1)	0.26
Herswab dry (HS)	284	60.9 (55.0, 66.6)	0.019	60	68.3 (55.0, 79.7)	0.033
Urine	504	72.2 (68.1, 76.1)	0.57	114	77.2 (68.4, 84.5)	0.19

Agreement between paired devices

	N	+/+	+/-	-/+	-/-	Agreement (%) (95% CI)
WD v DF	300	198	13	12	77	91.7 (87.9, 94.5)
QT v HS	280	163	22	10	85	88.6 (84.3, 92.1)
Urine v WD	249	155	22	17	55	84.3 (79.2, 88.6)
Urine v FS	249	156	21	16	56	85.1 (80.1, 89.3)
Urine v QT	252	157	29	10	56	84.5 (79.5, 88.8)
Urine v HS	240	143	36	9	52	81.3 (75.7, 86.0)

Internal (cellularity) control values, by device Ct values



Device	Median (Ct, IQR)
Wet Dacron	25.7 (1.6)
Dry Flocked	24.3 (2.1)
Qvintip	25.3 (3.2)
HerSwab	26.0 (6.1)
Urine	24.6 (2.8)

hrHPV positivity rates by device

- Adjusted for cellularity (and unadjusted)

		All sample	s	CIN2+			
Device		Positive (%) (95% CI)	P-value vs WD	N	Positive (%) (95% CI)	P-value vs WD	
Digene Wet Dacron	300	70.3 (70.3) (64.8, 75.4)		69	84.1 (73.3, 91.7)		
FLOQswab dry	300	62.7 (70.0) (56.9, 68.2)	0.057	69	79.7 (68.3, 88.4)	0.66	
Qvintip dry	295	65.1 (65.5) (59.3, 70.5)	0.19	62	80.6 (68.6, 89.6)	0.65	
Herswab dry	283	67.5 (60.9) (61.7, 72.9)	0.47	60	83.3 (71.5, 91.7)	1	

Higher Ct cutoff for HPV16 - unadjusted

Device	Н	IPV 16 Posit	ive defined as	≤ 34.2	HPV 16 Positive defined as ≤ 38.3			
	CIN2+	Sensitivity	<cin2< th=""><th>Specificity</th><th>CIN2+</th><th>Sensitivity</th><th><cin2< th=""><th>Specificity</th></cin2<></th></cin2<>	Specificity	CIN2+	Sensitivity	<cin2< th=""><th>Specificity</th></cin2<>	Specificity
Wet Dacron	59/69	85.5	150/229	34.5	62	89.9	151	34.1
FLOQswab	58/69	84.1	150/229	34.5	61	88.4	152	33.6
Qvintip	48/62	77.4	145/234	38.0	51	82.3	154	34.2
Herswab	41/60	68.3	132/224	41.1	49	81.7	136	39.3
Urine	88/114	77.2	274/388	29.4	99	86.8	282	27.3

Ease of Use

			Quite	Neither easy nor	Quite	Very		
Device	N	Very easy	easy	difficult	difficult	difficult	Excluded	Total
		128	91	19	9	0		
WD	247	(51.8%)	(36.8%)	(7.7%)	(3.6%)	(0.0%)	2	249
		155	71		8	1		
DF	247	(62.8%)	(28.7%)	12 (4.9%)	(3.2%)	(0.4%)	2	249
		119	87	35	13	0		
QT	254	(46.9%)	(34.3%)	(13.8%)	(5.1%)	(0.0%)	1	255
		108	89	25	29	3		
HS	254	(42.5%)	(35.0%)	(9.8%)	(11.4%)	(1.2%)	1	255
		304	146	29	17	5		
Urine	501	(60.7%)	(29.1%)	(5.8%)	(3.4%)	(1.0%)	3	504

Confidence in correctly using device

	N	Very confident	Fairly confident	Not confident	Excluded	Overall Total
		97	132	18		
WD	247	(39.3%)	(53.4%)	(7.3%)	2	249
		109	113	25		
DF	247	(44.1%)	(45.7%)	(10.1%)	2	249
		88	146	20		
QT	254	(34.6%)	(57.5%)	(7.9%)	1	255
		92	125	36		
HS	253	(36.4%)	(49.4%)	(14.2%)	2	255
		308	170			
Urine	500	(61.6%)	(34.0%)	22 (4.4%)	4	504

Conclusions

- Positivity rates for CIN2+ are lower than for clinically taken samples
 - Improved by higher C_t cutoff for HPV16
- Highest cellular yields for urine and FloQswab
 - Largest variation for HerSwab
- Digene Wet Dacron and FLOQswab produced similar and better results than Qvintip, Herswab and urine for raw values
 - More similar after adjustment for cell volume
- Referral population with high HPV positivity
 - Comparison with clinical samples and use in screening samples needed
- Less stringent cutoffs needed for self sampling (esp for HPV16)
 - consequences of false negatives more serious than false positives
 - eg base cutoff on 95% sensitivity for CIN2+